Polycyclo Ring System Patents (Class 514/680)
-
Publication number: 20090312437Abstract: Compositions derived from Rheum palmatum are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human.Type: ApplicationFiled: June 5, 2009Publication date: December 17, 2009Inventor: Isaac Cohen
-
Publication number: 20090312413Abstract: A composition comprising tanshinone compounds selected from the group consisting of miltirone, 1,2-didehydromiltirone, tanshinone IIA, tanshinone I and dihydrotanshinone I isolated from Salviae miltiorrhizae Bunge showing potent inhibiting effect on the aggregation and toxicity of beta-amyloid and recovering activity of memory learning disorder confirmed by Y maze study and Passive Avoidance study. Therefore it can be used as the therapeutics or health food for treating and preventing cognitive function disorder with safe.Type: ApplicationFiled: October 4, 2006Publication date: December 17, 2009Applicants: DIGITAL BIOTECH CO., LTD., ILSUNG PHARMACEUTICALS CO., LTD.Inventors: Sang Seob Song, Young Ho Kim, Jong Moon Kim, Hee Kim, Hee Jin Ha, Hoon Yi Jung
-
Publication number: 20090149551Abstract: 4b,5,6,7,8,8a-cis-hexahydro-2-hydroxy-4b,8,8a-trimethylphenanthren-9,10-dione (OHCT) is a fully oxidized compound based on the 2-hydroxy-cis-terpenone (HCT). Because OHCT is fully oxidized, it is more stable and less likely to damage cells or cell constituents such as DNA. OHCT has antimalarial activity, noncompetitive inhibitory activity against carcinogenic conversion of aflotoxin B1 (AFB1) to exo-AFB1-epoxide thus inihibiting AFB1 induced cellular toxicity, and inhibitory activity against TCDD induced cellular toxicity.Type: ApplicationFiled: August 22, 2008Publication date: June 11, 2009Inventors: Qibing Zhou, Ghislaine Mayer, Lin Zhang, Jennifer K. Stewart
-
Publication number: 20090137687Abstract: This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: June 19, 2008Publication date: May 28, 2009Applicants: OXiGENE, Inc., Baylor UniversityInventors: David Chaplin, Kevin G. Pinney, Peter Wardman, Vani P. Mocharla, Lisa K. Folkes
-
Publication number: 20090117040Abstract: The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.Type: ApplicationFiled: February 11, 2005Publication date: May 7, 2009Applicant: Max-Delbrug-Centrum Fur Molekulare MedizinInventors: Erich Wanker, Sabine Engemann, Susanne Rautenberg, Annett Boeddrich, Phoebe Markovic, Dagmar Ehrnhofer, Martin Herbst, Jacqueline Walther
-
Publication number: 20090110731Abstract: Particles are provided for use in restorative procedures to treat and/or retard alopecia The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in various colors or with customized coloration to match desired scalp colors. Moreover, such particles may be loaded to provide localized treatment with an active component agent directed at restoration of normal function and hair production within the hair follicle.Type: ApplicationFiled: October 30, 2007Publication date: April 30, 2009Applicant: CELONOVA BIOSCIENCES, INC.Inventors: Olaf Fritz, Ulf Fritz, Ronald Wojcik, Ralph E. Gaskins, JR.
-
Publication number: 20090099251Abstract: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or methoxycarbonyl; R9 is hydrogen, hydroxymethyl, methoxy, oxo or C1-5-acyloxy; R10 is hydrogen, or R5 and R9 taken together are —CH2—O— or —O—CH2—; or R5 and R10 taken together are —CO—O—, —O—CO—, —CH2—O— or —O—CH2—; R6 is hydrogen, or R5 and R6 together form a bond; R7 and R8 independently from each other are C1-6-alkyl, carboxy, x-hydroxy-Cx-alkyl (with x being an integer from 1 to 6), or C1-6-alkoxycarbonyl with the proviso that at least one of R7 and R8 is C1-6-alkyl; R11 and R12 are both hydrogen or R11 and R12 together are oxo, with the further proviso for formula (I) that if R2 is hydroxy R1 is C1-6-alkyl, for use as medicaments for the tType: ApplicationFiled: November 22, 2007Publication date: April 16, 2009Inventors: Antoine De Saizieu, Ann Fowler, Regina Goralczyk, Claus Kilpert, Goede Schueler, Christof Wehrli
-
Publication number: 20090082470Abstract: STAT3 inhibiting molecules and composition prevent intraoccular neovascularization and inflammation. STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of activity is shown to reduce intraoccular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents STAT3 from transcriptionally activating downstream gene targets that are known to be associated with retinal inflammation and neovascularization and such disorders as age-related macular degeneration.Type: ApplicationFiled: September 24, 2008Publication date: March 26, 2009Inventor: Rafal Farjo
-
Publication number: 20090068143Abstract: The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for prevention, alleviation or treatment of autoimmune neurodegenerative disorders, in particular multiple sclerosis and associated symptoms. Methods of the invention are useful when the active ingredient is administered alone or in combination with existing therapeutic modalities. The compositions are administered by oral route.Type: ApplicationFiled: February 24, 2005Publication date: March 12, 2009Applicant: PHARMOS CORPORATIONInventors: Avihai Yacovan, Avi Bar-Joseph, Sigal Meilin, Shimon Amselem
-
Patent number: 7488493Abstract: A performance aid for increasing the effectiveness of a bioactive agent, and a composition including both the performance and the bioactive agent. The performance aid increases the effectiveness of the bioactive agent by providing a composition that adheres well to a surface but also increases transferability of the bioactive agent to a target animal that contacts the treated surface.Type: GrantFiled: April 23, 2004Date of Patent: February 10, 2009Assignee: Arkion Life Sciences, LLCInventors: Kenneth E. Ballinger, Jr., Michele Santer
-
Publication number: 20080319067Abstract: The compounds of formula I in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as indicated in the description, are novel effective PDE4 inhibitors.Type: ApplicationFiled: December 17, 2007Publication date: December 25, 2008Inventors: Ulrich Kautz, Beate Schmidt
-
Publication number: 20080306164Abstract: The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17?-hydroxy steroid dehydro-genase type 1.Type: ApplicationFiled: August 15, 2008Publication date: December 11, 2008Inventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Gabriele Moeller, Dominga Deluca, Jerzy Adamski, Walter Elger, Birgitt Schneider
-
Patent number: 7435757Abstract: The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17?-hydroxy steroid dehydro-genase type 1.Type: GrantFiled: July 1, 2005Date of Patent: October 14, 2008Assignee: Schering AGInventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Gabriele Moeller, Dominga Deluca, Jerzy Adamski, Walter Elger, Birgitt Schneider
-
Patent number: 7432284Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Pagets disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.Type: GrantFiled: September 15, 2003Date of Patent: October 7, 2008Assignee: Merck & Co., Inc.Inventors: Dann LeRoy Parker, Robert R. Wilkening, Dongfang Meng, Ronald W. Ratcliffe
-
Patent number: 7432303Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: March 8, 2005Date of Patent: October 7, 2008Assignees: James and Emory UniversityInventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20080226759Abstract: A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive/addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient. The system further includes individual and group counseling and initial oxygen therapy. The genetic testing assesses the presence of gene polymorphism in at least one of D2 dopamine receptor gene (DRD2), dopamine transporter gene (DAT1), dopamine beta-hydroxylase gene (DBH) and serotonin transporter (SERT) gene. The dietary supplements are tailored to stimulate production of neuromediators or neurotransmitters, depending upon the polymorphism determined. The exercises include static and dynamic routines also tailored to the results of the genetic testing.Type: ApplicationFiled: March 15, 2007Publication date: September 18, 2008Inventor: Yakov Marshak
-
Publication number: 20080201871Abstract: Quaternary ammonium salts were incorporated into anthraquinone dyes via a stable linkage. The structure of the antimicrobial colorants were characterized by Fourier Transform Infrared (FTIR), Nuclear Magnetic Resonance (NMR) and UV-vis spectrometry. The dyes demonstrated excellent antimicrobial ability against both gram-negative and gram-positive bacteria in aqueous solution, as indicated by very low minimum inhibitory concentration (MIC). The colorants showed excellent stability in water under light, continuous heating as well as acidic and alkaline conditions.Type: ApplicationFiled: October 10, 2007Publication date: August 28, 2008Applicant: The Regents of the University of CaliforniaInventors: Gang Sun, Junshu Liu
-
Publication number: 20080161372Abstract: This invention relates to the treatment of hypertension, cardiac dysfunction or stroke by the administration of an estrogen receptor beta (ER&bgr;) selective agonist either as a single agent, or in combination with other agents.Type: ApplicationFiled: April 1, 2005Publication date: July 3, 2008Inventor: Susan P. Rohrer
-
Publication number: 20080102089Abstract: Various medical conditions previously treated by injection or surgery are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, varodilators and botulinum toxin. Conditions as diverse as spider veins, erectile dysfunction and facial wrinkles can be effectively treated with the compositions.Type: ApplicationFiled: October 30, 2006Publication date: May 1, 2008Inventor: John V. Cappello
-
Publication number: 20080027141Abstract: Disclosed herein are 1,3-dihydroxyl-9,10-anthraquinone and 3-[(3-amino)-propoxy]-9,10-anthraquinone derivatives, in particular 1,3-dihydroxy-4-prenyl-9,10-anthraquinone and 3-[3-(4-methylpiperazinyl)-propoxy]-9,10-anthraquinone, which are found to have inhibitory activities against several types of human tumor/cancer cells and thus can be used in the manufacture of pharmaceutical compositions for use in the treatment of tumors/cancers.Type: ApplicationFiled: July 5, 2006Publication date: January 31, 2008Applicant: Kaohsiung Medical UniversityInventors: Chun-Nan Lin, Shen-Jeu Won, Chi-Hung Teng
-
Patent number: 7265248Abstract: A colchicine derivative and a method of using a colchicine derivative as a pharmacological agent in the treatment of malaria are provided.Type: GrantFiled: April 28, 2006Date of Patent: September 4, 2007Assignee: Technology Innovations, LLCInventors: Jack A. Tuszynski, Stephen H. Curry
-
Patent number: 7230139Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.Type: GrantFiled: June 10, 2004Date of Patent: June 12, 2007Assignee: Gemin X BiotechnologiesInventors: Jean-Francois Lavallee, Terrence W. Doyle, Elise Rioux, Laurent Belec, Daniel Rabouin, Xavier Billot, Samuel Fortin
-
Patent number: 7217844Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.Type: GrantFiled: December 1, 2003Date of Patent: May 15, 2007Assignee: Gemin X BiotechnologiesInventors: Pierre Beauparlant, Giorgio Attardo, Zhiying Zhang, Angela M. Stafford, Rosa Ubillas, James B. McAlpine, Jean-Francois Lavallee, Samuel Fortin, Sasmita Tripathy
-
Patent number: 7157477Abstract: The invention involves a methods and compositions for use in photodynamic therapy. Novel perylenequinone derivatives, conjugates comprising perylenequinone derivatives and a binding agent, and methods of treatment using these compositions are disclosed. The present invention relates to the field of photosensitizers possessing photodynamic activities. They possess high photodynamic activities and low dark toxicities, which makes them as more potent photodynamic agents than HPD against cancer and AIDS virus.Type: GrantFiled: October 24, 2001Date of Patent: January 2, 2007Assignees: Altachem Pharma Ltd., Institute of Photographic Chemistry Academia SinicaInventors: Manhua Zhang, Shangjie Xu, Tao Wu, Shen Chen, Tao Shen
-
Patent number: 7151196Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.Type: GrantFiled: October 28, 2005Date of Patent: December 19, 2006Assignee: Merck & Co., Inc.Inventors: Robert R. Wilkening, Amy Fried
-
Patent number: 7122518Abstract: A method is provided for preventing or reducing the adverse effects of photodynamic therapy such as collateral damage by regulating the localized phototoxicity of an effector photosensitizer molecule. During photodynamic therapy, the activity of the effector photosensitizer molecule in neighboring tissues of the tissue targeted for destruction is quenched by a quenching photosensitizer molecule.Type: GrantFiled: November 25, 2003Date of Patent: October 17, 2006Assignee: New York UniversityInventor: Gad Lavie
-
Patent number: 7101917Abstract: Methods of utilizing compounds of general formulas I and II as modulators and affinity labels of the MPTP complex are elucidated. Furthermore, methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component are identified. Moreover, novel compounds of general formulas I and II are disclosed.Type: GrantFiled: April 5, 2004Date of Patent: September 5, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Andrea Cesura, Emmanuel Pinard
-
Patent number: 7087599Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.Type: GrantFiled: February 14, 2001Date of Patent: August 8, 2006Assignee: Merck & Co., Inc.Inventors: Dann LeRoy Parker, Jr., Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger
-
Patent number: 7060686Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.Type: GrantFiled: August 2, 2004Date of Patent: June 13, 2006Assignees: The Regents of the University of California, Florida Atlantic University Board of TrusteesInventors: Robert S. Jacobs, Russell G. Kerr
-
Patent number: 6958159Abstract: The present invention relates to an improved pharmaceutical composition useful for the topical treatment of burns, cuts, wounds, abrasions and the like, and to methods of treatment of injured body surfaces such as skin.Type: GrantFiled: March 26, 2001Date of Patent: October 25, 2005Assignee: Chiltern Pharmaceuticals, Pty Ltd.Inventor: Robert Alan Smith
-
Patent number: 6949250Abstract: We have now discovered that certain 9,10-anthraquinone derivatives we developed possess potent activity against O. perornata while possessing a sufficiently high level of solubility in water to make their activity against O. perornata viable. These compounds possess a high level of activity against O. perornata yet are relatively non-toxic to green algae and fishes. The compounds also possess a relatively short half-life. The compounds represent a new means to providing compounds possessing a high degree of selective activity against blue-green algae while being physiologically tolerated by catfish and green algae. The compounds provide a means for controlling blue-green algae in managed bodies of water that are destined for public use or consumption.Type: GrantFiled: December 16, 2002Date of Patent: September 27, 2005Assignees: The United States of America as represented by the Secretary of Agriculture, The University of MississippiInventors: Kevin K. Schrader, N. P. Dhammika Nanayakkara
-
Patent number: 6949557Abstract: The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.Type: GrantFiled: April 29, 2003Date of Patent: September 27, 2005Assignee: Dabur Research FoundationInventors: Asish Kumar Banerjee, Venkatachalam Sesha Giri, Rama Mukherjee, Kamal K. Kapoor, Gautam Desiraju, Manu Jaggi, Anu T. Singh, Sankar Kumar Dutta, Kalapatapu V. V. M. Sairam
-
Patent number: 6936571Abstract: The present invention provides an agricultural fungicidal composition containing active compounds selected from perylenequinonoid derivatives or salts thereof. The invention also relates the application of the composition against fungal plant infections.Type: GrantFiled: October 21, 2002Date of Patent: August 30, 2005Inventors: Hongyu Zhnag, Weizhong Liu
-
Patent number: 6906059Abstract: The use of benzazepin-N-acetic acid derivatives which contain an oxo group in the a position to the nitrogen atom and are substituted in the 3 position by a 1-(carboxyalkyl)-cyclopentyl-carbonyl-amino radical, and of their salts and biolabile esters, for the prophylaxis and/or treatment of heart damage caused by cardiotoxic doses of medicaments or chemicals, in larger mammals and in particular humans. The invention is particularly applicable to the prophylaxis and/or treatment of heart damage, in particular to the myocardium, which may occur during cytostatic chemotherapy. The invention also includes the use of the afore-mentioned benzazepin-N-acetic acid derivatives for adjuvant treatment in therapies in which medicaments having oxidative-toxic side-effects are used, and the preparation of medicaments suitable for this prophylaxis and/or treatment or adjuvant treatment.Type: GrantFiled: January 14, 2002Date of Patent: June 14, 2005Assignee: Solvay PharmaceuticalsInventors: Zsuzsanna Lonovics, Julius Gy. Papp, Dirk Thormaehlen, Harald Waldeck, Zsuzsanna Rozsa
-
Patent number: 6903238Abstract: This invention provides estrogen receptor modulators of formula I, having the structure R1, R2, and R3 are as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 11, 2002Date of Patent: June 7, 2005Assignee: WyethInventors: Robert E. McDevitt, Folake O. Adebi, Heather A. Harris, James C. Keith, Jr., Leo M. Albert
-
Patent number: 6894073Abstract: The disclosure concerns novel use of diterpene compound as a therapeutic agent of inlfammation, immune disease or cancer. More particularly, the present invention relates to novel use of diterpene compound that include kamebanin, kamebacetal A, kamebakaurin, and exisanin A, which would be effective for the treatment inflammation, immune disease or cancer by inhibiting the production of nitric oxide, prostaglandin, and TNF-a1 through the suppression of NF-k B activity.Type: GrantFiled: December 12, 2001Date of Patent: May 17, 2005Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Jung-Joon Lee, Jeong-Hyung Lee, Hang-Sub Kim, Young-Soo Hong, Bang-Yeon Hwang
-
Patent number: 6867235Abstract: Hypericin, helianthrone and derivatives thereof of general formula (I) wherein the dotted line between positions 11 and 12 represent an optional C11-C12 bond; R is independently selected from the group consisting of hydroxy, C1-C10 alkoxy, NH—C1-C10 alkyl, and NH-hydroxy(C1-C10)alkyl; R? is independently selected from the group consisting of hydroxy and C1-C10 alkoxy; R? is independently selected from the group consisting of hydrogen, hydroxy, C1-C10 alkoxy, NH—C1-C10 alkyl, and NH-hydroxy(C1-C10)alkyl; and R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy, chloro, bromo, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 alkoxycarbonyl, provided that R? is not hydrogen when there is a C11-C12 bond, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenosis and for the treatment of angiogenesis-associated ophthalmologic disorders.Type: GrantFiled: July 30, 2002Date of Patent: March 15, 2005Assignees: Yeda Research and Development Co. Ltd., New York UniversityInventors: Yehuda Mazur, Gad Lavie
-
Publication number: 20040248864Abstract: An anthroquinone such as diacerein is useful for the treatment of renal conditions and conditions (such as SLE) which lead to renal damage.Type: ApplicationFiled: July 30, 2004Publication date: December 9, 2004Inventors: Robin Mark Bannister, Alan Rothaul, Nicola Cooper
-
Publication number: 20040235783Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.Type: ApplicationFiled: June 29, 2004Publication date: November 25, 2004Inventors: Miklos Ghyczy, Jorg Hager, Armin Wendel
-
Publication number: 20040224926Abstract: A method for inhibiting or blocking molecular generating and/or inducing functions of molecules using an inhibitory or blocking agent of the formula: 1Type: ApplicationFiled: November 24, 2003Publication date: November 11, 2004Inventors: Shozo Koyama, Yoshihiro Yamaguchi
-
Publication number: 20040220257Abstract: Methods of utilizing compounds of general formulas I and II as modulators and affinity labels of the MPTP complex are elucidated. Furthermore, methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component are identified. Moreover, novel compounds of general formulas I and II are disclosed.Type: ApplicationFiled: April 5, 2004Publication date: November 4, 2004Inventors: Andrea Cesura, Emmanuel Pinard
-
Patent number: 6812255Abstract: The invention relates to the use of anti-cancer drug of a natural compound of vegetal origin, known as aloe-emodin (AE). Indeed, said compound has proved to have a specific biological activity of inhibition on the growth of neuroectodermal tumors, without evident toxic effects. The compound, according to the present invention, has also proved to be cell-specific and it does not show any inhibition on the growth of other cell types such as, for instance, fibroblasts. This pharmacological profile, i.e., tumor-targeting and absence of toxicity, makes said compound particularly advantageous in the treatment of neuroectodermal tumors. Pharmaceutical compositions containing said pharmacological agent can therefore be usefully used in the treatment of the foresaid pathologies.Type: GrantFiled: November 27, 2002Date of Patent: November 2, 2004Assignee: Universita Degli Studi Di PadovaInventors: Giorgio Palu′, Modesto Carli, Teresa Pecere
-
Publication number: 20040198827Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.Type: ApplicationFiled: April 27, 2004Publication date: October 7, 2004Applicant: Transition Therapeutics Inc., a Canada corporationInventors: Tony Cruz, Aleksandra Pastrak
-
Patent number: 6790463Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.Type: GrantFiled: March 30, 2001Date of Patent: September 14, 2004Inventors: Robert F. Hofmann, Robert H. Carpenter
-
Patent number: 6777447Abstract: Benzylidene cyclohexanone, cyclopentanone and acteone derivatives and therapeutic methods of using same are disclosed. The compounds are non-toxic and exhibit potent anti-inflammatory, antibacterial and antioxidation activity. Also, certain compounds of the invention inhibit glutathione S-transferase (“GST”), but do not irritate the gastrointestinal tract. Pharmaceutical compositions containing the compounds of the invention and pharmaceutically acceptable carriers are also disclosed.Type: GrantFiled: February 27, 2002Date of Patent: August 17, 2004Inventors: Mochammad Samhoedi Reksohadiprodjo, Henk Timmerman, Sardjiman Dummy, Supardjan Amir Margono, Sudibyo Martono, Sugiyanto Dummy, Lukman Rahman Hakim, Nurlaila Dummy, Arief Rahman Hakim, Ika Puspitasari, Arief Nurrochmad, Purwantiningsih Dummy, Oetari Dummy, Tedjo Yuwono
-
Patent number: 6773727Abstract: Low concentrations of gossypol and related phyllophage toxins from cotton improve the effectiveness of insecticidal agents against social insects, including cockroaches, and particularly termites and ants. Levels of gossypol and other cotton phyllophage toxins which are sufficiently low as to be non-biocidal to social insects alone, will significantly increase the control efficacy of other insecticidal agents. Consequently, use of these low levels of these cotton phyllophage toxins allows the levels of insecticidal agents necessary for effectively controlling the insects to be significantly reduced relative to applications without cotton phyllophage toxins. Furthermore, insecticidal agents which are normally ineffective for control of social insects when used alone, may be effective when used in conjunction with the cotton phyllophage toxins.Type: GrantFiled: August 13, 2001Date of Patent: August 10, 2004Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Maria G. Rojas, Juan A. Morales-Ramos, Peter J. Wan
-
Publication number: 20040152645Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo.Type: ApplicationFiled: January 20, 2004Publication date: August 5, 2004Applicants: Board of Trustees of Michigan State University, The Regents of the University of CaliforniaInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Publication number: 20040137088Abstract: The invention relates to an improved and stable (i.e. colour-stable and, optionally, stable with regard to its hyperforin content) extract from the overground parts of Hypericum perforatum L., to a method for the preparation thereof, and to pharmaceutical preparations and topical medicaments that contain this extract; in particular, gels for treating skin and mucous membrane irritations and disorders such as acne, atopic dermatitis, neuro-dermatitis, psoriasis, stomatitis, herpes zoster, herpes labialis (lip herpes), warts, varicella (chicken-pox), sores, burns and other bacterial and viral skin and mucous membrane infections and skin disorders that are accompanied by cell proliferation and inflammation.Type: ApplicationFiled: February 23, 2004Publication date: July 15, 2004Inventors: Egon Koch, Clemens Erdelmeier, Joachim Herrmann
-
Publication number: 20040121968Abstract: A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-&bgr;-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.Type: ApplicationFiled: December 23, 2002Publication date: June 24, 2004Inventors: Alexander Ljubimov, Raquel Castellon, Maria Grant
-
Patent number: RE39199Abstract: A psoriasis treatment composition derived from the plant Asphodelus Microcarpus includes 3-methylanthralin, chrysophanol, aloe-emodin, aloe-emodin monoacetate, and/or derivatives thereof. The composition is prepared by extracting a liquid from the Asphodelus Microcarpus root and mixing the liquid with acetic acid. A method of treatment includes applying the composition to an affected area of skin at a frequency sufficient to effect an alleviation of symptoms, typically once per day for 14-56 days.Type: GrantFiled: December 21, 2000Date of Patent: July 18, 2006Inventors: Naseba Moady, Marzook Moady